Industry News
Eye on emu for BioProspect
Termite foe BioProspect eyes off emu oil product range [ + ]
Macdonald goes permanent for stem cell centre
Graham Macdonald permanent chair of ASCC board of directors [ + ]
Elsevier published fake medical journals
Elsevier published six ‘fake’ Australian medical journals on behalf of pharma companies [ + ]
Australian Academy of Science awards for scientific excellence
The Australian Academy of Science 2009 winners of distinguished awards for scientific excellence have been announced.
[ + ]Top Australian and US scientists meet
Climate change, clean energy research and best practice approaches for providing expert advice to government were among the topics discussed when Prof Penny Sackett met with key US scientific advisers.
[ + ]Australian biotech market today 06.05.09
Cochlear, CSL, ResMed, Pharmaxis, Novogen, SciGen [ + ]
The complexity of the apicomplexans
The study of biology reveals some truly amazing and quite nifty feats of biochemical engineering, and none less so than the way in which parasitic microorganisms invade their host. [ + ]
Biotech profile: Novogen
Novogen has developed a technology platform based on synthetic isoflavones that promises compounds which can kill cancer cells without harming healthy cells. [ + ]
Australian biotech market today 05.05.09
COH, CSL, RMD, Pharmaxis, Sonic Healthcare, Avexa, Cellestis [ + ]
Pharmaxis progresses Bronchitol
Positive data from Pharmaxis’ Phase III trial in cystic fibrosis [ + ]
Trends in health and medical research funding
Research Australia has published 'Trends in Health and Medical Research Funding', a statistical overview of expenditure on health and medical research by government, industry and philanthropy.
[ + ]Profile: Implicit Biosciences
Brisbane biotech Implicit Bioscience has developed a business model unusual in Australia: it aims to return money to investors. [ + ]
Biotech profile: Hexima
Melbourne agbiotech Hexima has been making waves with its fungal and insect-resistance technology and a tasty deal with DuPont. [ + ]
Australian biotech market today 28.04.09
Biota, CSL, Hexima, Alchemia, Mesoblast [ + ]
Mesoblast fuses Phase II
Mesoblast approved for Phase II trail for cervical spine fusion [ + ]